Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × EPOCH protocol × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡